← Leaderboards
Eddy Hsueh
John Wayne Cancer Institute
$648,000
Attributed
$648,000
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$648,000 · 1
By mechanism
K08$648,000 · 1
Top collaborators
No co-investigators on record.
Most similar at John Wayne Cancer Institute
Same institution · by research overlap
- Donald L Morton$20,085,525
- Alistair J Cochran$1,667,088
- Dave S B Hoon$13,127,002
- Reiko F Irie$1,081,212
Others in their field
Top investigators on “Interleukin 4”
- Donald Ym Leung · University Of Colorado Denver$50,878,342
- Kent J. Weinhold · Duke University$45,381,151
- Paul M. Ridker · Brigham And Women'S Hospital$34,275,148
- Wanda Phipatanakul · Boston Children'S Hospital$22,736,067
- J. Mark Cline · Wake Forest University$20,130,326
- Charles A Coltman · Southwest Oncology Group$18,209,974
Research focus
Interleukin 4Gene Induction /RepressionColony Stimulating FactorNeoplasm /Cancer ImmunologyNeoplasm /Cancer ImmunotherapyNeoplasm /Cancer VaccineEnzyme Linked Immunosorbent AssayTumor Necrosis Factor AlphaCytotoxic T LymphocyteRadioimmunoassayCell Adhesion MoleculesVaccine DevelopmentClinical ResearchDelayed HypersensitivityFlow CytometryHistocompatibility AntigensHuman SubjectHuman Therapy EvaluationLeukocyte Adhesion MoleculesMelanoma
Grant awards (7)
ENHANCEMENT OF IMMUNOGENICITY OF HUMAN MELANOMA VACCINE$64,800
K08 · FY2005 · CA
ENHANCEMENT OF IMMUNOGENICITY OF HUMAN MELANOMA VACCINE$129,600
K08 · FY2004 · CA
ENHANCEMENT OF IMMUNOGENICITY OF HUMAN MELANOMA VACCINE$86,616
K08 · FY2003 · CA
ENHANCEMENT OF IMMUNOGENICITY OF HUMAN MELANOMA VACCINE$42,984
K08 · FY2003 · CA
ENHANCEMENT OF IMMUNOGENICITY OF HUMAN MELANOMA VACCINE$64,800
K08 · FY2002 · CA
ENHANCEMENT OF IMMUNOGENICITY OF HUMAN MELANOMA VACCINE$129,600
K08 · FY2001 · CA
ENHANCEMENT OF IMMUNOGENICITY OF HUMAN MELANOMA VACCINE$129,600
K08 · FY2000 · CA